AU2013316754A1 - Enzalutamide polymorphic forms and its preparation - Google Patents
Enzalutamide polymorphic forms and its preparation Download PDFInfo
- Publication number
- AU2013316754A1 AU2013316754A1 AU2013316754A AU2013316754A AU2013316754A1 AU 2013316754 A1 AU2013316754 A1 AU 2013316754A1 AU 2013316754 A AU2013316754 A AU 2013316754A AU 2013316754 A AU2013316754 A AU 2013316754A AU 2013316754 A1 AU2013316754 A1 AU 2013316754A1
- Authority
- AU
- Australia
- Prior art keywords
- enzalutamide
- solvent
- less
- crystalline
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
- H04W12/06—Authentication
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L65/00—Network arrangements, protocols or services for supporting real-time applications in data packet communication
- H04L65/10—Architectures or entities
- H04L65/1016—IP multimedia subsystem [IMS]
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L65/00—Network arrangements, protocols or services for supporting real-time applications in data packet communication
- H04L65/1066—Session management
- H04L65/1073—Registration or de-registration
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L65/00—Network arrangements, protocols or services for supporting real-time applications in data packet communication
- H04L65/40—Support for services or applications
- H04L65/4061—Push-to services, e.g. push-to-talk or push-to-video
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
- H04L9/40—Network security protocols
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
- H04W12/06—Authentication
- H04W12/069—Authentication using certificates or pre-shared keys
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
- H04W12/08—Access security
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
- H04W12/08—Access security
- H04W12/086—Access security using security domains
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/06—Selective distribution of broadcast services, e.g. multimedia broadcast multicast service [MBMS]; Services to user groups; One-way selective calling services
- H04W4/10—Push-to-Talk [PTT] or Push-On-Call services
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/90—Services for handling of emergency or hazardous situations, e.g. earthquake and tsunami warning systems [ETWS]
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W60/00—Affiliation to network, e.g. registration; Terminating affiliation with the network, e.g. de-registration
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W60/00—Affiliation to network, e.g. registration; Terminating affiliation with the network, e.g. de-registration
- H04W60/005—Multiple registrations, e.g. multihoming
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W76/00—Connection management
- H04W76/40—Connection management for selective distribution or broadcast
- H04W76/45—Connection management for selective distribution or broadcast for Push-to-Talk [PTT] or Push-to-Talk over cellular [PoC] services
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W76/00—Connection management
- H04W76/50—Connection management for emergency connections
Landscapes
- Engineering & Computer Science (AREA)
- Signal Processing (AREA)
- Computer Networks & Wireless Communication (AREA)
- Multimedia (AREA)
- Computer Security & Cryptography (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Business, Economics & Management (AREA)
- Public Health (AREA)
- General Business, Economics & Management (AREA)
- Environmental & Geological Engineering (AREA)
- Emergency Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3772CH2012 | 2012-09-11 | ||
IN3772/CHE/2012 | 2012-09-11 | ||
PCT/IB2013/058455 WO2014041487A2 (fr) | 2012-09-11 | 2013-09-11 | Formes polymorphes d'enzalutamide et leur préparation |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2013316754A1 true AU2013316754A1 (en) | 2015-04-30 |
Family
ID=50278792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013316754A Abandoned AU2013316754A1 (en) | 2012-09-11 | 2013-09-11 | Enzalutamide polymorphic forms and its preparation |
Country Status (14)
Country | Link |
---|---|
US (3) | US20150239848A1 (fr) |
EP (1) | EP2895464A4 (fr) |
JP (1) | JP2015534550A (fr) |
KR (1) | KR20150053963A (fr) |
CN (1) | CN104768935A (fr) |
AU (1) | AU2013316754A1 (fr) |
BR (1) | BR112015005404A2 (fr) |
CA (1) | CA2884640A1 (fr) |
IL (1) | IL237668A0 (fr) |
IN (1) | IN2015CH01921A (fr) |
MX (1) | MX2015003124A (fr) |
RU (1) | RU2015113434A (fr) |
WO (1) | WO2014041487A2 (fr) |
ZA (1) | ZA201502336B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3725778B1 (fr) | 2012-09-11 | 2021-08-18 | Medivation Prostate Therapeutics LLC | Formulations d'enzalutamide |
CN103910679B (zh) * | 2014-04-23 | 2016-05-25 | 杭州新博思生物医药有限公司 | 一种恩杂鲁胺的制备方法 |
EP3166931A4 (fr) * | 2014-07-11 | 2018-05-09 | Shilpa Medicare Limited | Procédé perfectionné pour la préparation d'enzalutamide |
CN104356068A (zh) * | 2014-10-30 | 2015-02-18 | 杭州新博思生物医药有限公司 | 恩杂鲁胺新晶型及其制备方法 |
CN106146403B (zh) * | 2015-04-02 | 2018-11-20 | 正大天晴药业集团股份有限公司 | 一种恩杂鲁胺的纯化方法 |
KR102369186B1 (ko) | 2015-04-02 | 2022-03-02 | 삼성전자 주식회사 | 서비스 등록 절차 내에서 다수의 인증을 수행하는 방법 |
MX2017014958A (es) * | 2015-05-29 | 2018-07-06 | Astellas Pharma Inc | Metodo de produccion de forma cristalina de enzalutamida. |
CN105030685B (zh) * | 2015-07-21 | 2018-02-27 | 福格森(武汉)生物科技股份有限公司 | 一种恩杂鲁胺固体分散体口服制剂 |
CA2996674A1 (fr) * | 2015-09-10 | 2017-03-16 | Jiangsu Hengrui Medicine Co., Ltd. | Forme cristalline d'un inhibiteur de recepteur d'androgene et son procede de preparation |
US11478453B2 (en) | 2016-07-21 | 2022-10-25 | Hadasit Medical Research Services And Development Ltd. | Treatment for glioblastoma |
US20200146977A1 (en) | 2017-04-28 | 2020-05-14 | Astellas Pharma Inc. | Pharmaceutical Composition for Oral Administration Comprising Enzalutamide |
CN111386257B (zh) * | 2017-11-28 | 2024-05-24 | 阿尔第药物实验室有限公司 | 使用新中间体制备恩杂鲁胺的方法 |
CZ2018234A3 (cs) | 2018-05-21 | 2019-12-04 | Zentiva Ks | Zvýšení rozpustnosti a biodostupnosti enzalutamidu |
CN110981812A (zh) * | 2019-11-25 | 2020-04-10 | 奥锐特药业股份有限公司 | 一种无定形恩杂鲁胺的制备方法 |
CN111217757B (zh) * | 2020-01-06 | 2021-03-19 | 武汉大学 | 一种恩杂鲁胺化合物及其药物组合物制剂 |
CN111303042A (zh) * | 2020-03-25 | 2020-06-19 | 北京赛思源生物医药技术有限公司 | 一种恩杂鲁胺的新晶型 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0901786B1 (fr) * | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Dispersions solides pharmaceutiques à biodisponibilité accrue |
IN191496B (fr) * | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
GB2383042A (en) * | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
WO2004074350A2 (fr) * | 2003-02-21 | 2004-09-02 | Hetero Drugs Limited | Bicalutamide polymorphe |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
KR101332924B1 (ko) * | 2005-05-13 | 2013-11-26 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
SG10201408699TA (en) | 2006-03-29 | 2015-02-27 | Univ California | Diarylthiohydantoin compounds |
DK3329775T3 (da) * | 2010-02-24 | 2021-07-26 | Medivation Prostate Therapeutics Llc | Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser |
-
2013
- 2013-09-11 RU RU2015113434A patent/RU2015113434A/ru not_active Application Discontinuation
- 2013-09-11 JP JP2015531667A patent/JP2015534550A/ja active Pending
- 2013-09-11 WO PCT/IB2013/058455 patent/WO2014041487A2/fr active Application Filing
- 2013-09-11 BR BR112015005404A patent/BR112015005404A2/pt not_active IP Right Cessation
- 2013-09-11 CN CN201380057085.0A patent/CN104768935A/zh active Pending
- 2013-09-11 MX MX2015003124A patent/MX2015003124A/es unknown
- 2013-09-11 US US14/427,527 patent/US20150239848A1/en not_active Abandoned
- 2013-09-11 EP EP13836427.8A patent/EP2895464A4/fr not_active Withdrawn
- 2013-09-11 KR KR1020157008879A patent/KR20150053963A/ko not_active Application Discontinuation
- 2013-09-11 AU AU2013316754A patent/AU2013316754A1/en not_active Abandoned
- 2013-09-11 CA CA2884640A patent/CA2884640A1/fr not_active Abandoned
-
2015
- 2015-03-11 IL IL237668A patent/IL237668A0/en unknown
- 2015-04-08 ZA ZA2015/02336A patent/ZA201502336B/en unknown
-
2016
- 2016-04-12 IN IN1921CH2015 patent/IN2015CH01921A/en unknown
- 2016-10-13 US US15/292,696 patent/US9701641B2/en not_active Expired - Fee Related
-
2017
- 2017-06-01 US US15/611,486 patent/US20170267645A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2014041487A3 (fr) | 2014-05-22 |
IL237668A0 (en) | 2015-04-30 |
KR20150053963A (ko) | 2015-05-19 |
US9701641B2 (en) | 2017-07-11 |
MX2015003124A (es) | 2015-10-12 |
JP2015534550A (ja) | 2015-12-03 |
ZA201502336B (en) | 2016-02-24 |
EP2895464A4 (fr) | 2016-06-15 |
BR112015005404A2 (pt) | 2017-08-22 |
IN2015CH01921A (fr) | 2016-07-01 |
CA2884640A1 (fr) | 2014-03-20 |
CN104768935A (zh) | 2015-07-08 |
US20150239848A1 (en) | 2015-08-27 |
WO2014041487A2 (fr) | 2014-03-20 |
US20170267645A1 (en) | 2017-09-21 |
RU2015113434A (ru) | 2016-11-10 |
EP2895464A2 (fr) | 2015-07-22 |
US20170029380A1 (en) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9701641B2 (en) | Enzalutamide polymorphic forms and its preparation | |
US9283210B2 (en) | Amorphous mirabegron and processes for crystal forms of mirabegron | |
US20160272627A1 (en) | Polymorphic forms of suvoroxant | |
WO2011130615A2 (fr) | Synthèse de lacosamide | |
US8779161B2 (en) | Asenapine maleate | |
US9045473B2 (en) | Forms of Apixaban | |
EP2358658A2 (fr) | Préparation de rasagiline et de ses sels | |
JP2020530473A (ja) | ロキサデュスタットの多形および共結晶 | |
WO2016027243A1 (fr) | Nouvelles formes solides de dimaléate d'afatinib | |
WO2012066565A2 (fr) | Maléate d'asénapine amorphe et forme cristalline et procédé pour leur préparation | |
WO2012106584A2 (fr) | Sels de pitavastatine | |
US10301353B2 (en) | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib | |
WO2015011659A1 (fr) | Formes polymorphes cristallines du régorafénib et méthodes de préparation de la forme polymorphe i du régorafénib | |
US9212172B2 (en) | Preparation of crystalline bazedoxifene and its salts | |
WO2013098773A1 (fr) | Formes cristallines de pitavastatine calcique | |
CA3206864A1 (fr) | Procede de preparation de mavacamten et formes a l'etat solide de celui-ci | |
WO2011139414A2 (fr) | Formes polymorphes de dexlansoprazole | |
TWI638810B (zh) | 氘代咪唑酮化合物之晶型i及其製備方法和用途 | |
WO2013008250A2 (fr) | Forme cristalline de la rétigabine et procédés de mélange de variétés cristallines de la rétigabine | |
SPECIFICATION | CRYSTALLINE FORMS OF MIRABEGRON AND PROCESS FOR THEIR PREPARATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |